CL
REGN icon

CIM LLC’s Regeneron Pharmaceuticals REGN Stock Holding History

CIM LLC’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,085
Closed -$780K – 153
2023
Q2 		$780K Hold
1,085
– – 0.15% 94
2023
Q1 		$892K Sell
1,085
-36
-3% -$27.2K 0.18% 86
2022
Q4 		$835K Sell
1,121
-67
-6% -$49.4K 0.17% 95
2022
Q3 		$903K Sell
1,188
-48
-4% -$30.2K 0.19% 88
2022
Q2 		$768K Sell
1,236
-33
-3% -$21.4K 0.16% 96
2022
Q1 		$917K Buy
+1,269
New +$803K 0.17% 88
2020
Q4 		– Sell
-1,100
Closed -$648K – 168
2020
Q3 		$648K Buy
1,100
+7
+0.6% +$4.24K 0.13% 103
2020
Q2 		$682K Buy
1,093
+26
+2% +$14.8K 0.2% 71
2020
Q1 		$521K Buy
+1,067
New +$440K 0.2% 67
2017
Q4 		– Sell
-978
Closed -$437K – 101
2017
Q3 		$437K Buy
978
+12
+1% +$5.71K 0.18% 67
2017
Q2 		$474K Buy
+966
New +$423K 0.2% 56

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

CIM LLC's REGN Position: Q3 2023 in Review

CIM LLC sold out of Regeneron Pharmaceuticals (REGN) in Q3 2023, closing a stake of 1,085 shares — an estimated $780K sold.

CIM LLC first reported a position in REGN in Q2 2017 and held it in 11 quarters. The position peaked at $917K in Q1 2022. 1,177 funds tracked by Wall St. Rank hold REGN as of Q3 2023.

  • CIM LLC reported no remaining Regeneron Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • CIM LLC sold 1,085 Regeneron Pharmaceuticals shares in Q3 2023, an estimated $780K.
  • CIM LLC first reported a position in Regeneron Pharmaceuticals in Q2 2017 and held it in 11 quarters.
  • CIM LLC's Regeneron Pharmaceuticals position peaked at $917K in Q1 2022.
  • 1,177 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2023.

Based on CIM LLC's 13F filing for Q3 2023, filed 17 May 2024.